McDonough & Novak Inc

Abveris is a leading antibody discovery company based in Canton, MA, specializing in the development of biologics for therapeutic and reagent antibody targets. With a strong reputation for delivering outstanding science, Abveris offers industry-leading antibody discovery solutions for challenging classes of targets, including cell surface receptors and difficult-to-target molecules such as GPCR and ion channels. Their end-to-end antibody discovery technologies, including repertoire generation, advanced screening, characterization, and recombinant expression, enable them to provide custom-built solutions for biotech and biopharma companies of all sizes. With expertise in antibody discovery and a fee-for-service, royalty-free partnership model, Abveris supports the development efforts of their partners in various fields, including cell therapies, point-of-care diagnostics, and clinical trials. Their proprietary hyperimmune mouse model, DiversimAb approach, and humanized mice enable rapid and high-resolution single B cell screening, epitope binning, and on-cell binding assays. Abveris' commitment to delivering high-quality clones and analytical data, along with their collaborative spirit, has earned them the trust of pharmaceutical and biotech companies in their pursuit of effective antibody discovery.Generated from the website

Charter Pre Clinical Services is a facility based in West Roxbury, MA that specializes in providing pre-clinical research services to pharmaceutical and biotechnology companies. With a focus on animal research models, the company offers a range of services to support drug development and testing. Utilizing state-of-the-art equipment and experienced staff, Charter Pre Clinical Services conducts studies in compliance with industry regulations and standards. Their expertise in pre-clinical research helps clients advance their drug discovery processes and bring new therapies to market. Generated from their business information

Lumicell is a pioneering company based in Wellesley, MA that is revolutionizing breast cancer surgery with its investigational fluorescence imaging technology. Their system is designed to provide real-time illumination of residual breast cancer during lumpectomy surgery, assisting in the detection of cancerous tissue within the lumpectomy cavity. With the potential to transform the current landscape of breast cancer surgery, Lumicell's transformative technology aims to evolve the standard of care in cancer surgery. Lumicell's innovative approach has garnered attention and recognition, with their co-founder Moungi Bawendi being awarded the Nobel Prize in Chemistry for his expertise in optics, fluorescent molecules, and tissue imaging. The company has also made significant strides in gaining regulatory approval, with the FDA accepting and prioritizing their New Drug Application for the LUMISIGHT Optical Imaging Agent and their Premarket Approval application for the Lumicell Direct Visualization System. Lumicell's commitment to advancing cancer surgery is further demonstrated by their recent appointment of Brent Palmisano as Chief Commercial Officer, as they prepare for the market launch of their groundbreaking technology.Generated from the website